[1]冷小飞,张逸群,魏 峰,等.长链非编码RNA RP11-572P18.1对卵巢癌细胞增殖和侵袭的影响及作用机制实验研究[J].陕西医学杂志,2024,(8):1011-1015,1020.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.001]
　LENG Xiaofei,ZHANG Yiqun,WEI Feng,et al.Effect of long non-coding RNA RP11-572P18.1 on the proliferation and invasion of ovarian cancer cells and its mechanism[J].,2024,(8):1011-1015,1020.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.001]
点击复制

长链非编码RNA RP11-572P18.1对卵巢癌细胞增殖和侵袭的影响及作用机制实验研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年8期
页码:
1011-1015,1020
栏目:
基础研究
出版日期:
2024-08-05

文章信息/Info

Title:
Effect of long non-coding RNA RP11-572P18.1 on the proliferation and invasion of ovarian cancer cells and its mechanism
作者:
冷小飞1; 张逸群1; 魏 峰1; 李 俊2; 朱颛顼1
(1.湖北医药学院附属十堰市太和医院妇产科,湖北 十堰 442000; 2.复旦大学附属中山医院肿瘤科,上海 200032)
Author(s):
LENG Xiaofei; ZHANG Yiqun; WEI Feng; LI Jun; ZHU Zhuanxu
(Department of Obstetrics and Gynecology,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,China)
关键词:
卵巢癌;  长链非编码RNA RP11-572P18.1;  微小RNA-205-5p;  细胞增殖;  细胞侵袭
Keywords:
Ovarian cancer;  Long non-coding RNA RP11-572P18.1;  miR-205-5p;  Cell proliferation;  Cell invasion
分类号:
R 36
DOI:
DOI:10.3969/j.issn.1000-7377.2024.08.001
文献标志码:
A
摘要:
目的:探讨长链非编码RNA(lncRNA)RP11-572P18.1对卵巢癌细胞增殖和侵袭的影响及其分子机制。方法:采用国际癌症基因组联盟(ICGC)数据库分析卵巢癌组织中RP11-572P18.1表达水平。实时荧光定量PCR(RT-qPCR)检测卵巢癌细胞系OC3、A2780、Caov-3、SK-OV-3、HO-8910中RP11-572P18.1表达水平,选取表达水平最低的细胞进行后续实验。将Caov-3细胞分为RP11-572P18.1组和NC组,分别转染RP11-572P18.1过表达质粒和对照质粒。MTT实验检测Caov-3细胞增殖能力,Transwell实验检测Caov-3细胞侵袭能力。双荧光素酶报告基因实验验证RP11-572P18.1和miR-205-5p的靶向关系。采用RT-qPCR检测Caov-3细胞miR-205-5p表达。采用免疫印迹法(Western blot)检测Caov-3细胞增殖蛋白[细胞周期蛋白B(Cyclin B)、细胞周期蛋白E(Cyclin E)]和侵袭蛋白[锌指E盒同源结合蛋白1(Zeb1)、转录因子(Twist)、β-连环蛋白(β-catenin)]表达。结果:与正常组织比较,卵巢癌组织中RP11-572P18.1表达降低(P<0.01)。与正常卵巢上皮细胞IOSE80比较,卵巢癌细胞系中RP11-572P18.1表达水平降低,且Caov-3细胞降低最显著(均P<0.05)。与NC组比较,RP11-572P18.1组Caov-3细胞增殖能力及侵袭数目降低(均P<0.05)。RP11-572P18.1与miR-205-5p存在靶向关系。与NC组比较,上调RP11-572P18.1可抑制Caov-3细胞miR-205-5p以及Cyclin B、Cyclin E、Zeb1、Twist和β-catenin蛋白表达(均P<0.05)。结论:RP11-572P18.1在卵巢癌组织和细胞系中表达降低,RP11-572P18.1通过下调miR-205-5p抑制卵巢癌细胞的增殖和侵袭。
Abstract:
Objective:To investigate the effects of long non-coding RNA(lncRNA)RP11-572P18.1 on the proliferation and invasion of ovarian cancer cells and its molecular mechanism.Methods:The expression level of RP11-572P18.1 in ovarian cancer tissues was analyzed using the international cancer genome consortium(ICGC)database.RT-qPCR was used to detect the expression levels of RP11-572P18.1 in ovarian cancer cell lines OC3,A2780,Caov-3,SK-OV-3 and HO-8910,and the cells with the lowest expression level were selected for follow-up experiments.The Caov-3 cells were divided into NC group and RP11-572P18.1 group,which were transfected with control plasmid and RP11-572P18.1 overexpression plasmid,respectively.MTT assay was used to detect the proliferation ability of Caov-3 cells,and Transwell assay was used to detect the invasion ability of Caov-3 cells.Dual luciferase reporter gene assay verified the targeting relationship between RP11-572P18.1 and miR-205-5p.The expression of miR-205-5p in Caov-3 cells was detected by RT-qPCR.Western blot was used to detect the expressions of proliferation proteins Cyclin B and Cyclin E and invasion proteins human Zinc finger E-box-binding homeobox 1(Zeb1),Twist and β-catenin in Caov-3 cells.Results:Compared with normal tissues,the expression of RP11-572P18.1 in ovarian cancer tissues was decreased(P<0.01).Compared with normal ovarian epithelial cells IOSE80,the expression of RP11-572P18.1 in ovarian cancer cell lines decreased,and the expression of Caov-3 cells decreased most significantly(all P<0.05).Compared with the NC group,the proliferation ability and invasion number of Caov-3 cells in the RP11-572P18.1 group decreased(all P<0.05).There was a targeting relationship between RP11-572P18.1 and miR-205-5p.Compared with the NC group,up-regulation of RP11-572P18.1 inhibited the expressions of miR-205-5p and Cyclin B,Cyclin E,Zeb1,Twist and β-catenin proteins in Caov-3 cells(all P<0.05).Conclusion:The expression of RP11-572P18.1 is decreased in ovarian cancer tissues and cell lines,and it can inhibit the proliferation and invasion of ovarian cancer Caov-3 cells by down-regulating miR-205-5p.

参考文献/References:

[1] LIU M,ZHANG H,LI Y,et al.Noncoding RNAs interplay in ovarian cancer therapy and drug resistance[J].Cancer Biother Radiopharm,2022,37(3):186-198.
[2] LIN H,XU X,CHEN K,et al.LncRNA CASC15,miR-23b cluster and SMAD3 form a novel positive feedback loop to promote epithelial-mesenchymal transition and metastasis in ovarian cancer[J].Int J Biol Sci,2022,18(5):1989-2002.
[3] LI P,HUANG G.Long noncoding RNA LINC00858 promotes the progression of ovarian cancer via regulating the miR-134-5p/TRIM44 axis[J].J Recept Signal Transduct Res,2022,42(4):382-389.
[4] LI H,LEI Y,LI S,et al.LncRNA PART1 stimulates the development of ovarian cancer by up-regulating RACGAP1 and RRM2[J].Reprod Sci,2022,29(8):2224-2235.
[5] CHEN X,YANG Y,SUN J,et al.LncRNA HCG11 represses ovarian cancer cell growth via AKT signaling pathway[J].J Obstet Gynaecol Res,2022,48(3):796-805.
[6] HE L,ZHU W,CHEN Q,et al.Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis[J].Theranostics,2019,9(26):8206-8220.
[7] LIU S,QIAO Z,MA Q,et al.LncRNA CYTOR and MIR4435-2HG in ovarian cancer and its relationship with clinicopathological features[J].Panminerva Med,2022,64(1):119-120.
[8] COBB L,GERSHENSON D.Novel therapeutics in low-grade serous ovarian cancer[J].Int J Gynecol Cancer,2023,33(3):377-384.
[9] KONSTANTINOPOULOS P A,MATULONIS U A.Clinical and translational advances in ovarian cancer therapy[J].Nat Cancer,2023,4(9):1239-1257.
[10] WANG W,KONG S,XU A.LncRNA ANRIL suppresses proliferation and promotes apoptosis of ovarian cancer cells by regulating miR-125a-3p/MAPK signaling pathway[J].Minerva Med,2022,113(3):581-582.
[11] 刘俊,曾龙,高云,等.长链非编码RNA YAF2-AS1通过调控微小RNA-141-3p表达抑制肝星状细胞活化实验研究[J].陕西医学杂志,2023,52(9):1120-1124.
[12] 孙玉苹,尹明亮,王文艳,等.四妙勇安汤对糖尿病足部溃疡患者血清lncRNA MALAT1表达量及足背血流动力学的影响[J].陕西中医,2023,44(8):1056-1060.
[13] TIAN J,YANG L,WANG Z,et al.MIR503HG impeded ovarian cancer progression by interacting with SPI1 and preventing TMEFF1 transcription[J].Aging(Albany NY),2022,14(13):5390-5405.
[14] LIN C,ZHENG M,YANG Y,et al.Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a[J].Bioengineered,2022,13(4):9829-9838.
[15] XU H,TANG Y,LIU L,et al.Downregulation of lncRNA ASMTL-AS1 in epithelial ovarian cancer correlates with worse prognosis and cancer progression[J].Horm Metab Res,2022,54(7):481-488.
[16] CHEN Y,CUI Z,WU Q,et al.Long non-coding RNA HOXA11-AS knockout inhibits proliferation and overcomes drug resistance in ovarian cancer[J].Bioengineered,2022,13(5):13893-13905.
[17] WANG S,WANG Y,LU J,et al.LncRNA LINC00665 promotes ovarian cancer cell proliferation and inhibits apoptosis via targeting miR-181a-5p/FHDC[J].Appl Biochem Biotechnol,2022,194(9):3819-3832.
[18] WANG Q,WANG L X,ZHANG C Y,et al.LncRNA CRNDE promotes cell proliferation,migration and invasion of ovarian cancer via miR-423-5p/FSCN1 axis[J].Mol Cell Biochem,2022,477(5):1477-1488.
[19] NAGHSH-NILCHI A,EBRAHIMI-GHAHNAVIEH L,DEHGHANIAN F.Construction of miRNA-lncRNA-mRNA co-expression network affecting EMT-mediated cisplatin resistance in ovarian cancer[J].J Cell Mol Med,2022,26(16):4530-4547.
[20] 王长亮,田文静,黄景荣,等.长链非编码RNA C16orf89在胃癌组织中的表达及对胃癌细胞增殖和侵袭的影响[J].陕西医学杂志,2023,52(6):635-639.
[21] 宇汝翠,陆智慧,李金虎,等.益气养阴通络方通过lncRNA UCA1靶向调控miR-485-5p抑制糖尿病肾病大鼠肾小管上皮细胞凋亡及炎症反应作用机制[J].陕西中医,2023,44(8):1000-1004.
[22] FANG W,XIA Y.LncRNA HLA-F-AS1 attenuates the ovarian cancer development by targeting miR-21-3p/PEG3 axis[J].Anticancer Drugs,2022,33(7):671-681.
[23] ZHAO Y L,ZHANG J X,YANG J J,et al.MiR-205-5p promotes lung cancer progression and is valuable for the diagnosis of lung cancer[J].Thorac Cancer,2022,13(6):832-843.
[24] YANG Y,XUN N,WU J G.Long non-coding RNA FGF14-AS2 represses proliferation,migration,invasion,and induces apoptosis in breast cancer by sponging miR-205-5p[J].Eur Rev Med Pharmacol Sci,2019,23(16):6971-6982.
[25] YANG W,TAN S,YANG L,et al.Exosomal miR-205-5p enhances angiogenesis and nasopharyngeal carcinoma metastasis by targeting desmocollin-2[J].Mol Ther Oncolytics,2022,24:612-623.

相似文献/References:

[1]刘瑞丽,刘小红,李会荣,等.主动循环腹腔热灌注化疗治疗卵巢癌伴腹腔积液效果观察*[J].陕西医学杂志,2019,(12):1630.
　LIU Ruili,LIU Xiaohong,LI Huirong,et al.Curative effect of active circulation intraperitoneal hyperthermic perfusion chemotherapy on ovarian cancer combined with seroperitoneum and its influences on prognosis[J].,2019,(8):1630.
[2]高 燕,杨 红,刘淑娟,等.线粒体动态蛋白在卵巢癌中的表达及临床意义[J].陕西医学杂志,2021,50(12):1589.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.031]
　GAO Yan,YANG Hong,LIU Shujuan,et al.Expression and clinical significance of mitochondrial dynamic protein of 51 kDa in ovarian cancer[J].,2021,50(8):1589.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.031]
[3]段小霞,郭 华,付 婷,等.震颤同系物-5过表达对卵巢癌细胞A2780增殖和凋亡的影响[J].陕西医学杂志,2022,51(5):529.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.004]
　DUAN Xiaoxia,GUO Hua,FU Ting,et al.Effect of quaking homolog-5 overexpression on proliferation and apoptosis of ovarian cancer cell line A2780[J].,2022,51(8):529.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.004]
[4]耿海慧,曹爱华.卵巢癌患者多种血清肿瘤标志物表达水平及其对疾病的诊断价值研究[J].陕西医学杂志,2022,51(7):886.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.029]
　GENG Haihui,CAO Aihua.Expression levels of various serum tumor markers in ovarian cancer patients and their diagnostic value for the disease[J].,2022,51(8):886.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.029]
[5]王 静,张虹宇,张 磊,等.动脉灌注分数联合转化生长因子-β及上皮细胞钙黏蛋白检测对原发性卵巢癌的诊断价值研究[J].陕西医学杂志,2023,52(7):858.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.019]
[6]王 静,张虹宇,张 磊,等.动脉灌注化疗联合细胞因子诱导杀伤细胞治疗晚期卵巢癌疗效及对患者血清癌胚抗原、糖类抗原125、可溶性B7-H4蛋白水平的影响[J].陕西医学杂志,2024,(2):199.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.011]
　WANG Jing,ZHANG Hongyu,ZHANG Lei,et al.Efficacy of arterial infusion chemotherapy combined with CIK in the treatment of advanced ovarian cancer and its effect on serum levels of carcinoembryonic antigen,carbohydrate antigen 125 and soluble B7-H4 protein[J].,2024,(8):199.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.011]
[7]刘玉锋,薛芳芳.卵巢癌患者造血前B细胞白血病转录因子相互作用蛋白表达和术前中性粒细胞与淋巴细胞比值水平及其临床检测价值[J].陕西医学杂志,2024,(5):662.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.019]
[8]司 晗,李洁妹,宗佳琪,等.高糖环境对卵巢癌细胞侵袭和迁移的影响及其机制实验研究[J].陕西医学杂志,2024,(8):1016.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.002]
　SI Han,LI Jiemei,ZONG Jiaqi,et al.Effect of high glucose environment on the invasion and migration of ovarian cancer cells and its mechanism[J].,2024,(8):1016.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.002]
[9]王 静,张虹宇,张 磊,等.长链非编码RNA PVT1调控表皮生长因子受体/有丝分裂原活性蛋白激酶通路对卵巢癌细胞的影响实验研究[J].陕西医学杂志,2024,(11):1454.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.003]
　WANG Jing,ZHANG Hongyu,ZHANG Lei,et al.Effect of long non-coding RNA PVT1 on ovarian cancer cells by regulating epidermal growth factor receptor/mitogen-activated protein kinase pathway[J].,2024,(8):1454.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.003]
[10]周佳敏,赵诗杰,朱小兰,等.RNA甲基化修饰在卵巢癌中的作用研究进展[J].陕西医学杂志,2024,(11):1571.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.029]
　ZHOU Jiamin,ZHAO Shijie,ZHU Xiaolan,et al.Research progress on the role of RNA methylation modifications in ovarian cancer[J].,2024,(8):1571.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.029]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81802596)
更新日期/Last Update: 2024-08-08